Journal of Medicinal Chemistry 2006-03-23

Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.

Hong-yu Li, Yan Wang, Charles R Heap, Chi-Hsin R King, Sreenivasa R Mundla, Matthew Voss, David K Clawson, Lei Yan, Robert M Campbell, Bryan D Anderson, Jill R Wagner, Karen Britt, Ku X Lu, William T McMillen, Jonathan M Yingling

Index: J. Med. Chem. 49 , 2138-2142, (2006)

Full Text: HTML

Abstract

Novel dihydropyrrolopyrazole-substituted benzimidazoles were synthesized and evaluated in vitro as inhibitors of transforming growth factor-beta type I receptor (TGF-beta RI), TGF-beta RII, and mixed lineage kinase-7 (MLK-7). These compounds were found to be potent TGF-beta RI inhibitors and selective versus TGF-beta RII and MLK-7 kinases. Benzimidazole derivative 8b was active in an in vivo target (TGF-beta RI) inhibition assay.

Related Compounds

Related Articles:

Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.

2003-09-11

[J. Med. Chem. 46 , 3953-3956, (2003)]

Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI).

2003-12-15

[Bioorg. Med. Chem. Lett. 13 , 4355-4359, (2003)]

Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta.

2006-11-10

[J. Biol. Chem. 281 , 33971-33981, (2006)]

A TGF-β receptor 1 inhibitor for prevention of proliferative vitreoretinopathy.

2014-06-01

[Exp. Eye Res. 123 , 72-86, (2014)]

Conditional ablation of TGF-β signaling inhibits tumor progression and invasion in an induced mouse bladder cancer model.

2016-01-01

[Sci. Rep. 6 , 29479, (2016)]

More Articles...